GPC3-MR-CAR T cells

GPC3-MR-CAR T cells are an experimental chimeric antigen receptor (CAR) T-cell therapy engineered to overcome the metabolic and immunosuppressive barriers of the solid tumor microenvironment, specifically for hepatocellular carcinoma (HCC). These cells are "metabolically refueled" (MR) through the co-expression of membrane-bound CD26 and cytoplasmic adenosine deaminase 1 (ADA1) fused to an anti-CD3 single-chain variable fragment (scFv). This genetic modification allows the T cells to convert extracellular adenosine—a potent immunosuppressive metabolite—into inosine. The T cells can then utilize inosine as an alternative carbon source to maintain growth, proliferation, and effector functions in nutrient-deprived environments. By targeting Glypican-3 (GPC3), a protein highly expressed in HCC, these cells provide a dual-action approach: direct tumor cell lysis and metabolic adaptation to the tumor microenvironment.

Other names

Metabolically refueled GPC3-targeted CAR T cellsMR-GPC3-CAR T cellsMR-GPC-3-CAR T cellsMR-GPC 3-CAR T cells